Asset Details
Do you wish to reserve the book?
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Do you wish to request the book?
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
2011
Overview
The initial encouraging activity of ruxolitinib in myelofibrosis appears to need some caveats when long-term efficacy is examined. The control of splenomegaly may not be durable, and the likelihood of leukemic progression or death is not dramatically lowered.
To the Editor:
JAK-STAT is an attractive drug target in patients with myelofibrosis because they often carry a
JAK2
mutation and also have an abnormally increased level of inflammatory cytokines.
1
Ruxolitinib (INCB018424) is a small-molecule ATP mimetic that inhibits both JAK1 and JAK2 and has been evaluated for its therapeutic activity in patients with myelofibrosis in phase 1, 2, and 3 clinical trials. The results of a phase 1/2 study of ruxolitinib involving 153 patients with myelofibrosis were recently published.
2
Our report constitutes a sponsor-independent analysis of long-term outcomes in the 51 patients at the Mayo Clinic who participated in . . .
Publisher
Massachusetts Medical Society
